The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
Cureus. 2021 May 20;13(5):e15141. doi: 10.7759/cureus.15141.
Haider Ghazanfar1, Sameer D Kandhi1, Iqra Nawaz1, Nismat Javed2, Minu C Abraham1, Mohamed Farag1, Jaydeep Mahasamudram1, Vishwa B Patel3, Faryal Altaf4, Harish Patel5
Author information
1Internal Medicine, BronxCare Health System, Bronx, USA.
2Internal Medicine, Shifa College of Medicine, Shifa Tameer-E-Millat University, Islamabad, PAK.
3Internal Medicine, St. George's University, St. George, GRD.
4Internal Medicine, Continental Medical College Lahore, Lahore, PAK.
5Medicine/Gastroenterology, BronxCare Health System, Bronx, USA.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the lethal causes of chronic liver disease globally. NAFLD can ultimately progress to non-alcoholic steatohepatitis (NASH) given persistent cellular insult. The crux of the problem lies in fat accumulation in the liver, such as increased fatty acid substrates owing to consumption of a high-fat diet, altered gut physiology, and excess adipose tissue. Being the hepatic manifestation of metabolic syndrome, insulin resistance is also among one of the many stimuli. Therefore, drugs, such as glucagon-like peptide-1 receptor agonist (GLP-1 RA) can play a significant role in reducing inflammation, in addition to weight loss and dietary habits. In this review article, we have reviewed the role of exenatide, liraglutide, and semaglutide in the management of NASH. Two of the agents, exenatide and semaglutide, have a predominant role in reducing alanine aminotransferase (ALT) levels, therefore reducing inflammation and promoting weight loss. However, these agents have a lesser impact on the degree of fibrosis. Liraglutide, on the other hand, has been shown to significantly decrease the degree of fibrosis and has been found helpful in reversing mild degrees of steatosis. Therefore, these agents warrant attention to the new perspective that has been presented so that future guidelines may incorporate and streamline individualized therapy.